Zobrazeno 1 - 10
of 2 855
pro vyhledávání: ''
Publikováno v:
Cancer Research and Treatment. 54:469-477
Purpose In hormone receptor-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+ HER2–MBC), the mainstay treatment options include cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and everolimus (EVE) in combi
Autor:
Yoshiaki Murakami, Shingo Seo, Hiroyuki Otsuka, Yasushi Hashimoto, Naru Kondo, Shinya Takahashi, Takeshi Sudo, Kenjiro Okada, Tatsuaki Sumiyoshi, Kenichiro Uemura
Publikováno v:
European Journal of Cancer. 159:215-223
Background The prognosis of patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A) is extremely poor, and effective preoperative treatment is indispensable. We evaluated the clinical efficacy and safety of neoadjuvant ch
Autor:
Bradley Curtis Carthon, Jesus Zoco, Thomas E. Hutson, Mark R. Olsen, Edward Arrowsmith, Johanna C. Bendell, Hamid Emamekhoo, Joshua Zhang, Daniel J. George, Scott S. Tykodi, David Leung, Ana M. Molina, Alexandra Drakaki, Lucio N. Gordan, Ivor John Percent, Daniel C. Cho, Jennifer L. Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Cancer. 128:966-974
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long-term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain metastases
Autor:
Shogo Teraoka, Atsushi Takenaka, Katsuya Hikita, Masashi Honda, Hideto Iwamoto, Shuichi Morizane, Bunya Kawamoto, Noriya Yamaguchi, Tetsuya Yumioka, Ryutaro Shimizu
Publikováno v:
Anticancer Research. 41:5767-5773
BACKGROUND This study aimed to investigate the response to platinum-based chemotherapy rechallenge in patients with pembrolizumab-refractory urothelial carcinoma. PATIENTS AND METHODS We retrospectively reviewed 14 patients with pembrolizumab-refract
Autor:
Xiaoyong Huang, Zhiqiang Wu, Wenbo Guo, Zhiyong Liu, Tengfei Li, Xu Bo, Weiguang Yu, Song Chen, Yanqing Wu, Pengfei Wang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents. The aim of this retrospective study was to assess the efficacy and safety of pembrol
Autor:
Koichi Inoue, Toshihiko Doi, Noboru Yamamoto, Yasutoshi Kuboki, Takafumi Koyama, Hiroya Asou, Naoto Tsujimoto, Yongzhe Piao, Yoichi Naito, Shunsuke Kondo
Publikováno v:
Cancer Medicine, Vol 10, Iss 19, Pp 6579-6589 (2021)
Cancer Medicine
Cancer Medicine
This phase 1, multi‐center, nonrandomized, open‐label, dose‐escalation study consisted of Part A wherein merestinib 80 or 120 mg (40‐mg tablets) was administered orally QD during a 28‐day cycle to patients diagnosed with solid tumors and Pa
Autor:
Patrick W. McGarrah, Christoph R. Becker, Rujuta Gadgil, Jennifer A. Chan, Pamela L. Kunz, Nitya Raj, Emily K. Bergsland, David Chan, Alia Thawer, Virginia Kelly, Linda Wu, Diane Lauren Reidy, Kathleen Hornbacker, Thorvardur R. Halfdanarson, Simron Singh, Julia Whitman
Publikováno v:
Oncologist
Background Grade 3 gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs) are often aggressive, and the optimal treatment is unclear for this subgroup of neuroendocrine neoplasms (NENs). Temozolomide (TEM)-based regimens have been increasingly
Autor:
Jing Shen, Jianmin Luo, Hang Su, Xi-Nan Cen, Aichun Liu, Quan-Shun Wang, Liping Su, Huilai Zhang, Jianxia He, Wei Zhang, Shuye Wang, Yuhuan Song, Daobin Zhou, Yuhuan Gao, Zengjun Li, Jing-Wen Wang, Hongmei Jing, Owen A. O'Connor, Hui Liu, Lihong Liu
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 3, Pp 841-848 (2021)
Cancer Biology & Medicine
Cancer Biology & Medicine
Objective: To assess the efficacy and safety of the novel histone deacetylase inhibitor, chidamide, in combination with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (Chi-CHOEP) for untreated peripheral T-cell lymphoma (PTCL).
Autor:
Rasmus T. Hoeg, Matthew E. Tenold, Rajeev Krishnan, Mehrdad Abedi, Brian A. Jonas, Aaron S. Rosenberg, Joseph Tuscano, Benjamin N Moskoff
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e611-e618
Background FLAG ± Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), is a salvage chemotherapy regimen for relapsed or refractory (R/R) acute myeloid leukemia (AML), with complete remission (CR) rates historically
Autor:
Félix Couture, Victoria Atkinson, Steven L. McCune, Alexander M. Menzies, Geoffrey T. Gibney, Andrew G. Hill, Georgina V. Long, Cuizhen Niu, Michael P. Brown, Blanca Homet Moreno, Stéphane Dalle, Steven J. O'Day, Caroline Robert, Matteo S. Carlino, Marcus O. Butler, Nageatte Ibrahim, Adi Diab, Jonathan Cebon
Publikováno v:
Clin Cancer Res
Purpose: Standard-dose pembrolizumab plus alternative-dose ipilimumab (1 mg/kg Q3W for 4 doses) were tolerable and had robust antitumor activity in advanced melanoma in cohort B of the phase 1 KEYNOTE-029 study. Cohort C evaluated standard-dose pembr